VERU INC. - COMMON STOCK

Veru Announces Date of 2024 Annual Meeting of Shareholders

01 أبريل 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Veru Reschedules Annual Meeting of Shareholders

22 مارس 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

12 مارس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

27 فبراير 2024 19:15:00 بحسب Nasdaq GlobeNewswire

Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

20 فبراير 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Veru Reports Fiscal 2024 First Quarter Financial Highlights

08 فبراير 2024 06:30:00 بحسب Nasdaq GlobeNewswire

Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs

06 فبراير 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

31 يناير 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024

25 يناير 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss

08 يناير 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs

19 ديسمبر 2023 08:30:00 بحسب Nasdaq GlobeNewswire

Veru Announces Pricing of Public Offering of Common Stock

14 ديسمبر 2023 09:00:00 بحسب Nasdaq GlobeNewswire

Veru Announces Proposed Public Offering of Common Stock

13 ديسمبر 2023 16:01:28 بحسب Nasdaq GlobeNewswire

Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasing Fat Loss in a Phase 2b Obesity Clinical Study

04 أكتوبر 2023 08:30:00 بحسب Nasdaq GlobeNewswire

Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)

26 سبتمبر 2023 08:30:00 بحسب Nasdaq GlobeNewswire

Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023

20 سبتمبر 2023 08:30:00 بحسب Nasdaq GlobeNewswire

Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer

11 سبتمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Veru to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023

30 أغسطس 2023 08:30:00 بحسب Nasdaq GlobeNewswire

Veru Reports Fiscal 2023 Third Quarter Financial Results

10 أغسطس 2023 06:30:00 بحسب Nasdaq GlobeNewswire

Veru to Report Fiscal 2023 Third Quarter Financial Results on August 10, 2023

03 أغسطس 2023 08:30:01 بحسب Nasdaq GlobeNewswire